Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors

Molecular Diversity

Volumn 13, Issue 3, 2009, Pages 301-311

  Melagraki, Georgia ^a,b,c   Afantitis, Antreas ^a,b,c,e   Sarimveis, Haralambos ^c   Koutentis, Panayiotis A ^d   Kollias, George ^e   Igglessi Markopoulou, Olga ^c  

^a NOVAMECHANICS LTD   (Cyprus)

^b Cyano Research Corporation Ltd   (Cyprus)

^c NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF CYPRUS   (Cyprus)

^e BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

HDAC; Histone deacetylases; Hydroxamic acids; In silico screening; QSAR

Indexed keywords

HISTONE DEACETYLASE INHIBITOR;

ARTICLE; DRUG ACTIVITY; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; IC 50; MULTIPLE LINEAR REGRESSION ANALYSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALGORITHMS; COMPUTER SIMULATION; DRUG DISCOVERY; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; MODELS, CHEMICAL; PHYSICOCHEMICAL PHENOMENA; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; THIOPHENES;

EID: 68349126938     PISSN: 13811991     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11030-009-9115-2     Document Type: Article

References (58)

1. V Santini A Gozzini G Ferrari 2007 Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application Curr Drug Metab 8 383 393 10.2174/138920007780655397 (Pubitemid 46780066)
2. G Elaut V Rogiers T Vanhaecke 2007 The pharmaceutical potential of histone deacetylase inhibitors Curr Pharm Des 13 2584 2620 10.2174/ 138161207781663064 (Pubitemid 47430437)
3. W An 2007 Histone acetylation and methylation: combinatorial players for transcriptional regulation Subcell Biochem 41 351 369
4. AJM de Ruijter AH van Gennip HN Caron S Kemp ABP van Kuilenburg 2003 Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem J 370 737 749 10.1042/BJ20021321 (Pubitemid 36399066)
5. WK Rasheed RW Johnstone HM Prince 2007 Histone deacetylase inhibitors in cancer therapy Expert Opin Investig Drugs 16 659 678 10.1517/13543784.16.5.659 (Pubitemid 46729100)
6. KV Balakin YA Ivanenkov AS Kiselyov SE Tkachenko 2007 Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective Anticancer Agents Med Chem 7 576 592
7. MA Glozak E Seto 2007 Histone deacetylases and cancer Oncogene 26 5420 5432 10.1038/sj.onc.1210610 (Pubitemid 47255924)
8. P Gallinari S Di Marco P Jones M Pallaoro C Steinkühler 2007 HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics Cell Res 17 195 211
9. CH Andrade LDB Salum MS Castilho KFM Pasqualoto EI Ferreira AD Andricopulo 2008 Fragment-based and classical quantitative structure-activity relationships for a series of hydrazides as antituberculosis agents Mol Divers 12 47 59
10. CW Yap H Li ZL Ji YZ Chen 2007 Regression methods for developing QSAR and QSPR models to predict compounds of specific pharmacodynamic, pharmacokinetic and toxicological properties Mini Rev Med Chem 7 1097 1107 10.2174/ 138955707782331696 (Pubitemid 350200216)
11. MS Castilho RVC Guido AD Andricopulo 2007 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors Bioorg Med Chem 15 6242 6252 10.1016/j.bmc.2007.06. 021 (Pubitemid 47088952)
12. G Melagraki A Afantitis H Sarimveis O Igglessi-Markopoulou A Alexandridis 2006 A novel RBF neural network training methodology to predict toxicity to Vibrio fischeri Mol Divers 10 213 221 10.1007/s11030-005-9008-y (Pubitemid 44092210)
13. A Afantitis G Melagraki H Sarimveis PA Koutentis J Markopoulos O Igglessi-Markopoulou 2006 A novel QSAR model for evaluating and predicting the inhibition activity of dipeptidyl aspartyl fluoromethylketones QSAR Comb Sci 25 928 935 10.1002/qsar.200530208 (Pubitemid 44621668)
14. K Roy 2006 Ecotoxicological modeling and risk assessment using chemometric tools Mol Divers 10 93 94 10.1007/s11030-006-9025-5 (Pubitemid 44092199)
15. B Xia W Ma B Zheng X Zhang B Fan 2008 Quantitative structure-activity relationship studies of a series of non-benzodiazepine structural ligands binding to benzodiazepine receptor Eur J Med Chem 43 1489 1498 10.1016/j.ejmech.2007.09.004 (Pubitemid 351885213)
16. G Melagraki A Afantitis K Makridima H Sarimveis O Igglessi-Markopoulou 2006 Prediction of toxicity using a novel RBF neural network training methodology J Mol Model 12 297 305 10.1007/s00894-005-0032-8 (Pubitemid 43337199)
17. A Tropsha A Golbraikh 2007 Predictive QSAR modeling workflow, model applicability domains, and virtual screening Curr Pharm Des 13 3494 3504 10.2174/138161207782794257 (Pubitemid 350238939)
18. I Muegge S Oloff 2006 Advances in virtual screening Drug Discov Today Technol 3 405 411
19. A Afantitis G Melagraki H Sarimveis PA Koutentis J Markopoulos O Igglessi-Markopoulou 2006 Investigation of substituent effect of 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides amides on CCR5 binding affinity using QSAR and virtual screening techniques J Comput Aided Mol Des 20 83 95 10.1007/s10822-006-9038-2 (Pubitemid 43899119)
20. G Melagraki A Afantitis H Sarimveis PA Koutentis J Markopoulos O Igglessi-Markopoulou 2007 Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure Bioorg Med Chem 15 7237 7247 10.1016/j.bmc.2007.08.036 (Pubitemid 47539153)
21. G Melagraki A Afantitis H Sarimveis PA Koutentis J Markopoulos O Igglessi-Markopoulou 2007 Optimization of biaryl piperidine and 4-amino-2-biarylurea MCH1 receptor antagonists using QSAR modeling, classification techniques and virtual screening J Comput Aided Mol Des 21 251 267 10.1007/s10822-007-9112-4 (Pubitemid 46630053)
22. RVC Guido G Oliva AD Andricopulo 2008 Virtual screening and its integration with modern drug design technologies Curr Med Chem 15 37 46 10.2174/092986708783330683 (Pubitemid 351234626)
23. H-F Chen J-h Kang Q Li B-s Zeng X-j Yao B-t Fan S-g Yuan A Panay JP Doucet 2003 3D-QSAR study on apicidin inhibit histone deacetylase Chin J Chem 21 1596 1607
24. A Xie C Liao Z Li Z Ning W Hu X Lu L Shi J Zhou 2004 Quantitative structure-activity relationship study of histone deacetylase inhibitors Curr Med Chem Anticancer Agents 4 273 299 10.2174/1568011043352948 (Pubitemid 38647587)
25. D-F Wang O Wiest P Helquist H-Y Lan-Hargest NL Wiech 2004 QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids Bioorg Med Chem Lett 14 707 711 10.1016/j.bmcl.2003.11.062 (Pubitemid 38114857)
26. B Liu A-J Lu C-Z Liao H-B Liu J-J Zhou 2005 3D-QSAR of sulfonamide hydroxamic acid HDAC inhibitors Acta Physi-Chim Sin 21 333 337
27. Y Guo J Xiao Z Guo F Chu Y Cheng S Wu 2005 Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses Bioorg Med Chem 13 5424 5434 10.1016/j.bmc.2005.05.016 (Pubitemid 41132620)
28. R Ragno S Simeoni S Valente S Massa A Mai 2006 3-D QSAR studies on histone deacetylase inhibitors A GOLPE/GRID approach on different series of compounds. J Chem Inf Model 46 1420 1430 10.1021/ci050556b (Pubitemid 43999186)
29. R Ragno S Simeoni D Rotili A Caroli G Botta G Brosch S Massa A Mai 2008 Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-DQSAR, homology and docking studies Eur J Med Chem 43 621 632 10.1016/j.ejmech.2007.05.004 (Pubitemid 351323996)
30. DC Juvale VV Kulkarni HS Deokar NK Wagh SB Padhye VM Kulkarni 2006 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues Org Biomol Chem 4 2858 2868 10.1039/b606365a (Pubitemid 44100284)
31. NK Wagh HS Deokar DC Juvale SS Kadam VM Kulkarni 2006 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation Indian J Biochem Biophys 43 360 371
32. D Jaiswal C Karthikeyan SK Shrivastava P Trivedi 2006 QSAR modeling of sulfonamide inhibitors of histone deacetylase Internet Electron J Mol Des 5 345 354
33. S Vadivelan BN Sinha G Rambabu K Boppana SARP Jagarlapudi 2008 Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads J Mol Graph Model 26 935 946 10.1016/j.jmgm.2007.07.002
34. Y-D Chen Y-J Jiang J-W Zhou Q-S Yu Q-D You 2008 Identification of ligand features essential for HDACs inhibitors by pharmacophore modelling J Mol Graph Model 26 1160 1168 10.1016/j.jmgm.2007.10.007
35. S Price W Bordogna RJ Bull DE Clark PH Crackett HJ Dyke M Gill NV Harris J Gorski J Lloyd PM Lockey J Mullett AG Roach F Roussel AB White 2007 Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)- thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors Bioorg Med Chem Lett 17 370 375 10.1016/j.bmcl.2006.10.048 (Pubitemid 46073757)
36. S Price W Bordogna R Braganza RJ Bull HJ Dyke S Gardan M Gill NV Harris RA Heald M van den Heuvel PM Lockey J Lloyd AG Molina AG Roach F Roussel JM Sutton AB White 2007 Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors Bioorg Med Chem Lett 17 363 369 10.1016/j.bmcl.2006.10.045 (Pubitemid 46073760)
37. JJP Stewart 2007 Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements J Mol Model 13 1173 1213 10.1007/s00894-007-0233-4 (Pubitemid 47629446)
38. CambridgeSoft Corporation ChemOffice. http://www.cambridgesoft.com
39. MOPAC2007 Stewart JJP, Stewart Computational Chemistry, Version 7.295W web: http://OpenMOPAC.net
40. Svozil D, Lohninger H TOPIX. http://www.lohninger.com/topix.html
41. RW Kennard LA Stone 1969 Computer aided design of experiments Technometrics 11 137 148 10.2307/1266770
42. G Melagraki A Afantitis K Makridima H Sarimveis O Igglessi-Markopoulou 2006 Prediction of toxicity using a novel RBF neural network training methodology J Mol Model 12 297 305 10.1007/s00894-005-0032-8 (Pubitemid 43337199)
43. A Afantitis G Melagraki H Sarimveis PA Koutentis J Markopoulos O Igglessi-Markopoulou 2006 A novel QSAR model for predicting induction of apoptosis by 4-aryl-4H-chromenes Bioorg Med Chem 14 6686 6694 10.1016/j.bmc.2006.05.061 (Pubitemid 44233302)
44. AK Chakraborti B Gopalakrishnan ME Sobhia A Malde 2003 3D-QSAR studies of indole derivatives as phosphodiesterase IV inhibitors Eur J Med Chem 38 975 982 10.1016/j.ejmech.2003.09.001 (Pubitemid 37452424)
45. A Afantitis G Melagraki H Sarimveis PA Koutentis J Markopoulos O Igglessi-Markopoulou 2006 A novel QSAR model for evaluating and predicting the inhibition of dipeptidyl aspartyl fluoromethylketones QSAR Comb Sci 25 928 935 10.1002/qsar.200530208 (Pubitemid 44621668)
46. P Ghosh M Thanadath MC Bagchi 2006 On an aspect of calculated molecular descriptors in QSAR studies of quinolone antibacterials Mol Divers 10 415 427 10.1007/s11030-006-9018-4 (Pubitemid 46156696)
47. W Wu B Walczak DL Massart S Heuerding F Erni IR Last KA Prebble 1996 Artificial neural networks in classification of NIR spectral data: design of the training set Chemom Intell Lab Syst 33 35 46 10.1016/0169-7439(95)00077-1 (Pubitemid 26168648)
48. Todeschini R, Consonni V, Mannhold R (2000) In: Kubinyi H, Timmerman H (Series Ed.) Handbook of molecular descriptors. Wiley-VCH, Weinheim
49. A Tropsha P Gramatica VK Gombar 2003 The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models QSAR Comb Sci 22 69 77 10.1002/qsar.200390007
50. A Golbraikh A Tropsha 2002 Beware of q 2 J Mol Graph Model 20 269 276 10.1016/S1093-3263(01)00123-1 (Pubitemid 34017544)
51. G Melagraki A Afantitis H Sarimveis O Igglessi-Markopoulou A Alexandridis 2006 A novel RBF neural network training methodology to predict toxicity to Vibrio fischeri Mol Divers 10 213 221 10.1007/s11030-005-9008-y (Pubitemid 44092210)
52. M Jalali-Heravi A Kyani 2007 Application of genetic algorithm-kernel partial least square as a novel nonlinear feature selection method: activity of carbonic anhydrase II inhibitors Eur J Med Chem 42 649 659 10.1016/j.ejmech. 2006.12.020 (Pubitemid 46719494)
53. A Afantitis G Melagraki H Sarimveis PA Koutentis J Markopoulos O Igglessi-Markopoulou 2006 A novel simple QSAR model for the prediction of anti-HIV activity using multiple linear regression analysis Mol Divers 10 405 414 10.1007/s11030-005-9012-2 (Pubitemid 46150636)
54. M Petitjean 1992 Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds J Chem Inf Comput Sci 32 331 337 10.1021/ci00008a012
55. G Melagraki A Afantitis H Sarimveis O Igglessi-Markopoulou CT Supuran 2006 QSAR study on para-substituted aromatic sulfonamides as carbonic anhydrase II inhibitors using topological information indices. Bioorg Med Chem 14 1108 1114 10.1016/j.bmc.2005.09.038 (Pubitemid 43059802)
56. AT Balaban 1982 Highly discriminating distance-based topological index Chem Phys Lett 89 399 404 10.1016/0009-2614(82)80009-2
57. A Tropsha A Golbraikh 2007 Predictive QSAR modeling workflow, model applicability domains, and virtual screening Curr Pharm Des 13 3494 3504 10.2174/138161207782794257 (Pubitemid 350238939)
58. M Hewitt MTD Cronin JC Madden PH Rowe C Johnson A Obi SJ Enoch 2007 Consensus QSAR models: do the benefits outweigh the complexity J Chem Inf Model 47 1460 1468 10.1021/ci700016d (Pubitemid 47210049)